APA (7th ed.) Citation

Kiesewetter, B., Mazal, P., Kretschmer-Chott, E., Mayerhoefer, M., & Raderer, M. (2022). Pulmonary neuroendocrine tumours and somatostatin receptor status: An assessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO open, 7(3), 100478. https://doi.org/10.1016/j.esmoop.2022.100478

Chicago Style (17th ed.) Citation

Kiesewetter, B., P. Mazal, E. Kretschmer-Chott, M.E Mayerhoefer, and M. Raderer. "Pulmonary Neuroendocrine Tumours and Somatostatin Receptor Status: An assessment of Unlicensed Use of Somatostatin Analogues in the Clinical Practice." ESMO Open 7, no. 3 (2022): 100478. https://doi.org/10.1016/j.esmoop.2022.100478.

MLA (9th ed.) Citation

Kiesewetter, B., et al. "Pulmonary Neuroendocrine Tumours and Somatostatin Receptor Status: An assessment of Unlicensed Use of Somatostatin Analogues in the Clinical Practice." ESMO Open, vol. 7, no. 3, 2022, p. 100478, https://doi.org/10.1016/j.esmoop.2022.100478.